[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 140
66. Jung SH, Paik CN, Jung JH, Lee KM, Chung WC, Yang JM: Simultaneous Colonic Obstruction and Hydroureteronephrosis due to Mesenteric Fibromatosis. Gut Liver; 2009 Sep;3(3):215-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous Colonic Obstruction and Hydroureteronephrosis due to Mesenteric Fibromatosis.
  • Mesenteric fibromatosis (MF) is a rare benign mesenchymal lesion that can occur throughout the gastrointestinal tract, especially small bowel.
  • Its biological behavior is intermediate between benign fibrous tissue proliferation and malignant fibrosarcoma.
  • In previously reported cases of MF, we could find colonic obstruction or ureter obstruction, but simultaneous involvement of colon and ureter was not able to be seen.
  • We described a patient that presented with colonic obstruction and hydroureteronephrosis due to MF at sigmoid colon which mimicked submucosal tumor such as gastrointestinal tumor.
  • This case resulted in a positive positron emission tomography scan suggesting malignant neoplasm, but beta-catenin positivity on immunohistochemical staining separated MF from gastrointestinal stromal tumor and sclerosing mesenteritis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2007 Dec 7;13(45):5985-8 [18023087.001]
  • [Cites] Dis Colon Rectum. 2007 Jun;50(6):924-6 [17205200.001]
  • [Cites] World J Gastroenterol. 2005 Sep 7;11(33):5226-8 [16127758.001]
  • [Cites] Histopathology. 1994 Nov;25(5):469-73 [7532614.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):947-57 [10895817.001]
  • [Cites] AJR Am J Roentgenol. 1991 Aug;157(2):275-9 [1853806.001]
  • [Cites] Am J Surg Pathol. 1990 Apr;14(4):335-41 [2321698.001]
  • [Cites] Am J Clin Pathol. 2004 Jan;121(1):93-8 [14750246.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1296-301 [12360044.001]
  • [Cites] AJR Am J Roentgenol. 1991 Mar;156(3):539-42 [1899752.001]
  • (PMID = 20431749.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2852704
  • [Keywords] NOTNLM ; Colonic obstruction / Hydroureteronephrosis / Mesenteric fibromatosis
  •  go-up   go-down


67. Iwai T, Kudo T, Kawamoto R, Kubota T, Togayachi A, Hiruma T, Okada T, Kawamoto T, Morozumi K, Narimatsu H: Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proc Natl Acad Sci U S A; 2005 Mar 22;102(12):4572-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells.
  • In normal stomach and colon, beta3Gn-T6 was strongly expressed in the Golgi region of epithelia.
  • Tissue specimens from a familial adenomatous polyposis patient showed a clear correlation between the down-regulation of beta3Gn-T6 expression and the degree of dysplasia/neoplasia.
  • These results suggested that the expression of beta3Gn-T6 is closely regulated during differentiation and dedifferentiation. beta3Gn-T6 would be a useful marker for distinguishing between benign adenomas and premalignant lesions.
  • [MeSH-major] Colonic Neoplasms / enzymology. Colonic Neoplasms / genetics. N-Acetylglucosaminyltransferases / genetics. N-Acetylglucosaminyltransferases / physiology
  • [MeSH-minor] Animals. Caco-2 Cells. Cell Line, Tumor. Cell Movement / physiology. Colorectal Neoplasms / enzymology. Colorectal Neoplasms / genetics. Down-Regulation. Humans. Immunohistochemistry. In Vitro Techniques. Lung Neoplasms / enzymology. Lung Neoplasms / genetics. Lung Neoplasms / secondary. Mice. Mice, Inbred BALB C. Stomach Neoplasms / enzymology. Stomach Neoplasms / genetics. Transfection

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10231-3 [12149519.001]
  • [Cites] J Biol Chem. 2002 Jun 21;277(25):22623-38 [11925450.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):573-84 [12407114.001]
  • [Cites] Anal Biochem. 1976 Aug;74(2):466-76 [962103.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2051-5 [6952252.001]
  • [Cites] J Natl Cancer Inst. 1983 Aug;71(2):231-51 [6576183.001]
  • [Cites] Cancer Res. 1985 Jun;45(6):2405-14 [3886132.001]
  • [Cites] J Biol Chem. 1985 Jul 15;260(14):8262-71 [4008490.001]
  • [Cites] Biochemistry. 1985 Apr 9;24(8):1866-74 [3160388.001]
  • [Cites] J Natl Cancer Inst. 1985 Sep;75(3):447-54 [2863413.001]
  • [Cites] J Biol Chem. 1985 Dec 15;260(29):15510-5 [4066681.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):67-95 [10580130.001]
  • [Cites] J Soc Biol. 1999;193(1):85-99 [10851560.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Jan;280(1):L181-7 [11133508.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 May;280(5):G1043-8 [11292614.001]
  • [Cites] Biochem J. 2001 Sep 15;358(Pt 3):657-64 [11577689.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):178-86 [11677243.001]
  • [Cites] Cancer Res. 1986 May;46(5):2627-32 [3516383.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4841-7 [3731131.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3239-45 [2438036.001]
  • [Cites] Nature. 1987 Aug 13-19;328(6131):614-6 [3039373.001]
  • [Cites] Cancer Res. 1988 Jul 1;48(13):3834-42 [3288336.001]
  • [Cites] J Biol Chem. 1988 Oct 15;263(29):15146-50 [2971663.001]
  • [Cites] Cancer Res. 1989 Feb 1;49(3):745-52 [2910493.001]
  • [Cites] J Biol Chem. 1991 Jan 25;266(3):1772-82 [1824844.001]
  • [Cites] Genomics. 1991 Oct;11(2):247-51 [1663069.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1199-211 [1312973.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1993 Jun;48(6):423-8 [8341719.001]
  • [Cites] Eur J Biochem. 1994 Jun 1;222(2):415-24 [8020479.001]
  • [Cites] Glycobiology. 1994 Dec;4(6):873-84 [7734850.001]
  • [Cites] Glycobiology. 1995 May;5(3):351-7 [7655172.001]
  • [Cites] Eur J Biochem. 1995 Oct 15;233(2):607-17 [7588808.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2237-44 [8625291.001]
  • [Cites] Gastroenterology. 1996 May;110(5):1354-67 [8613039.001]
  • [Cites] Cell Biol Int. 1997 May;21(5):281-7 [9243803.001]
  • [Cites] Biochemistry. 1998 Apr 7;37(14):4916-27 [9538010.001]
  • [Cites] Keio J Med. 1998 Mar;47(1):10-8 [9560527.001]
  • [Cites] Clin Exp Metastasis. 1998 Apr;16(3):267-74 [9568644.001]
  • [Cites] Biochemistry. 1999 May 25;38(21):6817-25 [10346903.001]
  • [Cites] J Biol Chem. 1999 Jul 23;274(30):21209-16 [10409676.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4083-9 [10463611.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):12802-9 [11821425.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47724-31 [12361956.001]
  • (PMID = 15755813.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.4.1.- / N-Acetylglucosaminyltransferases; EC 2.4.1.- / UDP-GlcNAc GalNAc-peptide beta1,3-N-acetylglucosaminyltransferase
  • [Other-IDs] NLM/ PMC555466
  •  go-up   go-down


68. Nocito A, Hahnloser D: [Indications for laparoscopic colorectal resections--also for cancers?]. Ther Umsch; 2005 Feb;62(2):119-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the last decade, laparoscopy has dramatically changed colonic surgery.
  • Laparoscopic procedures are applied to the treatment of almost all colonic diseases, including both benign and malignant lesions.
  • Significant benefits can be expected with a laparoscopic approach relative to decreased pain, ileus, length of hospital stay, disability, and possibly, adhesion formation and subsequent bowel obstruction, and improved cosmesis.
  • However, all those benefits are secondary in the treatment of cancer; tumor-free survival must be the primary goal.
  • [MeSH-major] Colectomy / methods. Colonic Diseases / surgery. Colorectal Neoplasms / surgery. Laparoscopy. Rectal Diseases / surgery

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756922.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 73
  •  go-up   go-down


69. Galitskiĭ MV, Khomeriki SG, Nikiforov PA: [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy]. Eksp Klin Gastroenterol; 2009;(5):28-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy].
  • Permanent type of the bile flow provokes the increase of proliferation of colic epithelial cells and increases the risk for development of right-sided colorectal tumors.
  • Meanwhile morphological features of colorectal tumors at the patients with cholecystectomy are still remaining to be clarified.
  • Fifty patients (40 with retained function of gallbladder and 10 patients with cholecystectomy) histologically diagnosed as proximal colon adenoma or adenocarcinoma were included into the study.
  • In addition, biopsies have been taken from the adjacent healthy colon mucosa at least 5 cm from the lesion in each patient.
  • 83 tumors and 49 samples of mucosa were immunostained with monoclonal mouse anti-human p53 protein (Dako) and monoclonal mouse anti-human Ki-67 antigen (Novocastra).
  • The index of Ki-67 expression in healthy colon mucosa at the patients with cholecystectomy was 37,5 +/- 1,8% (p < 0,05) as compared to 31,36 +/- 1,9 at the patients without cholecystectomy.
  • Thus, in benign colorectal tumors at the patients with retained function of gallbladder intensifying of epithelial cells proliferation is not accompanied with intensifying of apoptosis, and in malignant tumors a complete supression of apoptosis is observed.
  • The retaining of apoptosis in colorectal tumors compensates intensive proliferative activity with expectation of better prognosis.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / biosynthesis. Cell Proliferation. Cholecystectomy. Colon / metabolism. Colonic Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Intestinal Mucosa / metabolism. Ki-67 Antigen / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205327.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


70. Oishi K, Fukuda S, Sakimoto H, Eto T, Takahashi M, Nishida T: Angiomyolipoma of the colon: report of a case. Surg Today; 2009;39(11):998-1001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiomyolipoma of the colon: report of a case.
  • Angiomyolipomas are benign mesenchymal tumors mostly arising from the kidney.
  • Angiomyolipoma of the colon is extremely rare.
  • Here we report the findings of a 51-year-old man who presented with a submucosal tumor covered with normal mucosa and hemorrhage in the descending colon.
  • He underwent a partial resection of the descending colon.
  • A histopathological examination showed that the tumor of 5.7 cm in diameter included smooth muscle (spindle cell type), mature adipose tissue, and vessels, and therefore a diagnosis of angiomyolipoma was made.
  • A submucosal type of angiomyolipoma of the colon is extremely rare.
  • When colonoscopy shows a submucosal tumor of the colon with hemorrhage, angiomyolipoma should be considered.
  • If an angiomyolipoma of the colon is large, surgical resection should be considered as a treatment option due to the risk of hemorrhage.
  • [MeSH-major] Angiolipoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):523-9 [11914633.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):547-9 [12682553.001]
  • [Cites] Radiology. 2002 Oct;225(1):78-82 [12354988.001]
  • [Cites] Surg Today. 2008;38(6):529-35 [18516533.001]
  • [Cites] Kidney Int. 2006 Nov;70(10):1777-82 [17003820.001]
  • [Cites] Mod Pathol. 1999 Dec;12(12):1132-6 [10619265.001]
  • [Cites] Radiology. 2004 Mar;230(3):677-84 [14990834.001]
  • [Cites] Am J Gastroenterol. 1996 Sep;91(9):1852-4 [8792714.001]
  • [Cites] J Urol. 1951 Apr;65(4):525-7 [14825528.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Sep;3(9):A35 [16234016.001]
  • [Cites] Int J Urol. 2005 Feb;12(2):204-7 [15733117.001]
  • [Cites] Gastroenterol Jpn. 1989 Aug;24(4):407-9 [2777016.001]
  • [Cites] Gastrointest Endosc. 2006 Sep;64(3):443-4; discussion 444 [16923501.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1315-25 [12352384.001]
  • [Cites] Radiology. 1997 Nov;205(2):497-502 [9356635.001]
  • (PMID = 19882325.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


71. Weinstein A, Nouri K, Bassiri-Tehrani S, Flores F, Jimenez G: Muir-Torre syndrome: a case of this uncommon entity. Int J Dermatol; 2006 Mar;45(3):311-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition to BCC, she had been treated for breast cancer, colon cancer, and cervical cancer prior to emigrating to the USA.
  • Her colonic malignancy had been localized proximal to the splenic flexure.
  • She also had a history of colonic polyps and distal colonic villous adenoma.
  • Her family history was significant for a sister with colon cancer and transitional cell carcinoma of the urinary bladder.
  • No further treatment was required for these benign sebaceous tumors, but their presence defined our patient's condition as Muir-Torre syndrome.
  • Mohs' micrographic surgery was performed on the tragus BCC and the margins were tumor free in one stage.
  • [MeSH-major] Breast Neoplasms / complications. Carcinoma, Basal Cell / complications. Colonic Neoplasms / complications. Skin Neoplasms / complications. Uterine Cervical Neoplasms / complications


72. Misra S, Toole BP, Ghatak S: Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem; 2006 Nov 17;281(46):34936-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hyaluronan (HA) is enriched in the pericellular matrices of many malignant human tumors, and manipulations of HA interactions have strong effects on tumor progression in animal models.
  • On the other hand, inhibition of constitutive HA-tumor cell interactions in malignant cells inhibits these properties.
  • IGF1R-beta, PDGFR-beta, EGFR and c-MET, in colon, prostate, and breast carcinoma cells.
  • On the other hand, we show that these RTKs are activated in phenotypically normal or relatively benign tumor cells by experimentally increasing HA production.
  • In HCA7 colon and C4-2 prostate carcinoma cells, ERBB2 is constitutively activated in a ligand-independent manner, whereas IGF1R-beta and PDGFR-beta require ligand interaction for activation.
  • [MeSH-minor] Breast Neoplasms / metabolism. Cell Line, Tumor. Colonic Neoplasms / metabolism. Female. Humans. Male. Prostatic Neoplasms / metabolism. Signal Transduction


73. Chen YY, Soon MS: Preoperative diagnosis of colonic angiolipoma: a case report. World J Gastroenterol; 2005 Aug 28;11(32):5087-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative diagnosis of colonic angiolipoma: a case report.
  • Angiolipoma, a common benign tumor mostly seen in the subcutaneous tissue, is a rare pathological condition in the gastrointestinal tract that is usually diagnosed postoperatively.
  • [MeSH-major] Angiolipoma / radiography. Colonic Neoplasms / radiography. Preoperative Care. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • Hazardous Substances Data Bank. Barium, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16124075.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 24GP945V5T / Barium
  • [Other-IDs] NLM/ PMC4321939
  •  go-up   go-down


7
Advertisement
4. Wagner M, Loos J, Weksler N, Gantner M, Corless CL, Barry JM, Beer TM, Garzotto M: Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Biochem Biophys Res Commun; 2005 Jul 8;332(3):800-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Targeting of cyclooxygenase-2 (COX-2) for cancer chemoprevention is well supported for several tumor types, most notably colon cancer.
  • Thus, we compared the COX-2 expression, activity, and effects of inhibition in prostate cancer cells on COX-2-dependent colon cancer cells.
  • COX-2 levels in benign and malignant human prostate tissue were determined by immunohistochemistry.
  • Compared to colon cancer cells, prostate cancer cells expressed lower levels of COX-2, produced less PGE2, and were resistant to selective COX-2 inhibition.
  • Examination of benign prostatic epithelium from prostatectomy samples demonstrated rare foci of COX-2.
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Colonic Neoplasms / metabolism. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Dinoprostone / biosynthesis. Drug Resistance, Neoplasm. Humans. Immunohistochemistry. Male. Membrane Proteins. Nitrobenzenes / pharmacology. Sulfonamides / pharmacology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15907789.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 69533
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Membrane Proteins; 0 / Nitrobenzenes; 0 / Sulfonamides; 123653-11-2 / N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


75. Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P, Ruiz i Altaba A: Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med; 2009 Sep;1(6-7):338-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion.
  • Human colon cancers often start as benign adenomas through loss of APC, leading to enhanced beta CATENIN (beta CAT)/TCF function.
  • We find that epithelial cells of human colon carcinomas (CCs) and their stem cells of all stages harbour an active HH-GLI pathway.
  • Moreover, using a novel tumour cell competition assay we show that the self-renewal of CC stem cells in vivo relies on HH-GLI activity.
  • Targeting HH-GLI1, directly or indirectly, is thus predicted to decrease tumour bulk and eradicate CC stem cells and metastases.
  • [MeSH-major] Carcinoma / metabolism. Colonic Neoplasms / metabolism. Epithelial Cells / metabolism. Hedgehog Proteins / metabolism. Neoplastic Stem Cells / cytology. Transcription Factors / metabolism
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cells, Cultured. Gene Expression Regulation, Neoplastic. Humans. Mice. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Signal Transduction / drug effects. Veratrum Alkaloids / therapeutic use

  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2006 Feb 20;233(1):117-23 [16473672.001]
  • [Cites] Virchows Arch. 2009 Apr;454(4):369-79 [19280222.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] Development. 2001 Dec;128(24):5201-12 [11748155.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Development. 2004 Jan;131(2):337-45 [14681189.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):277-82 [14770182.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]
  • [Cites] J Pathol. 2004 Aug;203(4):909-17 [15258993.001]
  • [Cites] Dev Biol. 2004 Sep 15;273(2):257-75 [15328011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Teratology. 1970 May;3(2):175-80 [4986632.001]
  • [Cites] Lipids. 1978 Oct;13(10):708-15 [723484.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] Nature. 1997 Oct 23;389(6653):876-81 [9349822.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Development. 1998 Sep;125(18):3553-62 [9716521.001]
  • [Cites] Development. 1999 Jun;126(14):3205-16 [10375510.001]
  • [Cites] Development. 2005 Jan;132(2):279-89 [15590741.001]
  • [Cites] Mech Dev. 2005 Feb;122(2):223-30 [15652709.001]
  • [Cites] Oncogene. 2006 Jan 26;25(4):609-21 [16158046.001]
  • [Cites] Gastroenterology. 2009 Jun;136(7):2187-2194.e1 [19324043.001]
  • [Cites] Surgery. 2006 May;139(5):665-70 [16701100.001]
  • [Cites] Gut. 2006 Jul;55(7):991-9 [16299030.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] J Gastroenterol. 2006 Dec;41(12):1238-9 [17287906.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900 [17392427.001]
  • [Cites] World J Gastroenterol. 2007 Mar 21;13(11):1659-65 [17461467.001]
  • [Cites] Trends Cell Biol. 2007 Sep;17(9):438-47 [17845852.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2622-7 [17683069.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):638-48 [17932721.001]
  • [Cites] Cell Stem Cell. 2007 Oct 11;1(4):389-402 [18371377.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13427-32 [18765800.001]
  • [Cites] Nature. 2008 Sep 18;455(7211):406-10 [18754008.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):281-3 [18835029.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):603-7 [19092805.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4254-9 [19246386.001]
  • [Cites] EMBO J. 2009 Mar 18;28(6):663-76 [19214186.001]
  • [CommentIn] EMBO Mol Med. 2010 Oct;2(10):385-6; author reply 386-7 [20721989.001]
  • [CommentIn] EMBO Mol Med. 2009 Sep;1(6-7):300-2 [20049733.001]
  • (PMID = 20049737.001).
  • [ISSN] 1757-4684
  • [Journal-full-title] EMBO molecular medicine
  • [ISO-abbreviation] EMBO Mol Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Transcription Factors; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ PMC3378144
  •  go-up   go-down


76. Pagnotta E, Calonghi N, Boga C, Masotti L: N-methylformamide and 9-hydroxystearic acid: two anti-proliferative and differentiating agents with different modes of action in colon cancer cells. Anticancer Drugs; 2006 Jun;17(5):521-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-methylformamide and 9-hydroxystearic acid: two anti-proliferative and differentiating agents with different modes of action in colon cancer cells.
  • Both agents show the same anti-proliferative effects by arresting colon cancer cell growth in G0/G1.
  • The effects of NMF and 9-HSA on growth, differentiation and invasiveness of HT29, a colon cancer cell line, have been compared by using immunoprecipitation analysis, confocal microscopy, enzyme assays and invasiveness tests.
  • Evidence is presented that the arrest in early G0/G1 induced by 9-HSA is associated with the conversion of HT29 characteristics to those of a more benign phenotype, whereas the arrest in the late G1 in response to NMF is not followed by a decrease in tumorigenicity.
  • [MeSH-major] Colonic Neoplasms / drug therapy. Formamides / pharmacology. Stearic Acids / pharmacology
  • [MeSH-minor] Cell Cycle / drug effects. Cell Differentiation / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cytoskeleton / drug effects. Humans. Microscopy, Confocal

  • Hazardous Substances Data Bank. N-METHYLFORMAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702808.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Formamides; 0 / Stearic Acids; 3384-24-5 / 9-hydroxystearic acid; XPE4G7Y986 / methylformamide
  •  go-up   go-down


77. Sieren LM, Collins JN, Weireter LJ, Britt RC, Reed SF, Novosel TJ, Britt LD: The incidence of benign and malignant neoplasia presenting as acute appendicitis. Am Surg; 2010 Aug;76(8):808-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of benign and malignant neoplasia presenting as acute appendicitis.
  • We sought to review our experience with neoplasia presenting as appendicitis.
  • Ten patients (7.1%) were diagnosed with neoplasia on final pathology, including four women and six men with a mean age of 46.9 years and mean duration of symptoms of 12.6 days.
  • Final pathology revealed four colonic adenocarcinoma; three mucinous tumors; one carcinoid; one endometrioma; and one patient had a combination of a mucinous cystadenoma, a carcinoid tumor, and endometriosis of the appendix.
  • Colonic and appendiceal neoplasia are not unusual etiologies of appendicitis.

  • MedlinePlus Health Information. consumer health - Appendicitis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20726408.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Matsumoto T, Hirano S, Yada K, Shibata K, Sasaki A, Kamimura T, Ohta M, Kitano S, Kashima K: Malignant serous cystic neoplasm of the pancreas: report of a case and review of the literature. J Clin Gastroenterol; 2005 Mar;39(3):253-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant serous cystic neoplasm of the pancreas: report of a case and review of the literature.
  • BACKGROUND: In general, serous cystic neoplasms of the pancreas are thought to be benign.
  • Malignant serous cystic neoplasm of the pancreas is a rare clinical entity.
  • CASE REPORT: We report the case of an 87-year-old woman with a serous microcystic neoplasm in the tail of the pancreas that behaved in a malignant fashion.
  • The neoplasm had also invaded the colonic mesentery and splenic hilum.
  • The pancreatic lesion was diagnosed as a large malignant serous cystic neoplasm, and the patient underwent distal pancreatectomy with splenectomy and segmental colectomy.
  • The resected specimen contained a large tumor, 12 x 9 x 8 cm, which occupied the body and tail of the pancreas.
  • Histologically, the tumor was indistinguishable from serous cystadenoma.
  • However, the tumor had invaded surrounding tissues including the splenic vein, and there were splenic invasion and a regional lymph node metastasis.
  • DISCUSSION: There are few reported cases of malignant serous cystic neoplasm, in which malignancy was histologically confirmed in the resected specimen.
  • There are no reports of a negative outcome with complete resection of the tumor.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15718870.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


79. Coons SW, Estrada SI, Gamez R, White WL: Cytokeratin CK 7 and CK 20 expression in pituitary adenomas. Endocr Pathol; 2005;16(3):201-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because pituitary tumors are almost always benign, there has been little interest in their cytokeratin profile.
  • However, we recently reported the use of CK 7/20 expression to document malignant progression and metastasis of a pituitary tumor, indicating the potential diagnostic usefulness of the CK 7/20 profile of pituitary adenomas.
  • This CK 20-positive, CK 7-negative profile is previously described consistently only in colonic adenocarcinomas.
  • [MeSH-major] Adenoma / metabolism. Biomarkers, Tumor / metabolism. Intermediate Filament Proteins / metabolism. Keratins / metabolism. Pituitary Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):870-6 [10843291.001]
  • [Cites] Endocrinol Metab Clin North Am. 1999 Mar;28(1):13-43, v-vi [10207684.001]
  • [Cites] Am J Clin Pathol. 1994 Dec;102(6):764-7 [7528468.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):804-12 [9024719.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):119-26 [9490269.001]
  • [Cites] Mod Pathol. 1995 May;8(4):384-8 [7567935.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):171-7 [9921990.001]
  • [Cites] Endocr Pathol. 1996 Summer;7(2):145-150 [12114642.001]
  • (PMID = 16299403.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / CAM 5.2 antigen; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


80. Huo Q: Protein complexes/aggregates as potential cancer biomarkers revealed by a nanoparticle aggregation immunoassay. Colloids Surf B Biointerfaces; 2010 Jul 1;78(2):259-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study examined four biomarkers proteins, CA125, CEA (carcinoembryonic antigen), CA19-9 and PAP (prostatic acid phosphatase) in ovarian, colon and prostate tissue lysates.
  • The most exciting results were observed from the PAP assay of prostate tissues: prostate cancer can be clearly distinguished from normal prostate and prostate with benign conditions such as BPH (benign prostate hyperplasia) based on the complex/aggregation level of PAP in prostate tissue lysates.
  • [MeSH-major] Biomarkers, Tumor / analysis. Immunoassay / methods. Metal Nanoparticles / chemistry. Neoplasms / metabolism. Proteins / analysis
  • [MeSH-minor] Acid Phosphatase. Adult. Aged. Aged, 80 and over. Antibodies / chemistry. CA-125 Antigen / analysis. CA-125 Antigen / chemistry. CA-19-9 Antigen / analysis. CA-19-9 Antigen / chemistry. Carcinoembryonic Antigen / analysis. Carcinoembryonic Antigen / chemistry. Colonic Neoplasms / diagnosis. Colonic Neoplasms / metabolism. Diagnosis, Differential. Female. Gold / chemistry. Humans. Male. Membrane Proteins / analysis. Membrane Proteins / chemistry. Middle Aged. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / metabolism. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / metabolism. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / metabolism. Protein Binding. Protein Conformation. Protein Tyrosine Phosphatases / analysis. Protein Tyrosine Phosphatases / chemistry. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20392611.001).
  • [ISSN] 1873-4367
  • [Journal-full-title] Colloids and surfaces. B, Biointerfaces
  • [ISO-abbreviation] Colloids Surf B Biointerfaces
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / MUC16 protein, human; 0 / Membrane Proteins; 0 / Proteins; 7440-57-5 / Gold; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


81. Gobet R, Weber D, Renzulli P, Kellenberger C: Long-term follow up (37-69 years) of patients with bladder exstrophy treated with ureterosigmoidostomy: uro-nephrological outcome. J Pediatr Urol; 2009 Jun;5(3):190-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient suffered from adenocarcinoma of the colon, five had benign colonic polyps, one urethral papillary carcinoma and 18 no evidence of tumor.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adolescent. Adult. Aged. Carcinoma, Papillary / epidemiology. Child. Child, Preschool. Colonic Neoplasms / epidemiology. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Urinary Incontinence / epidemiology. Urination. Urolithiasis / epidemiology

  • Genetic Alliance. consumer health - Exstrophy of the Bladder.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136304.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


82. Lisovsky M, Dresser K, Baker S, Fisher A, Woda B, Banner B, Lauwers GY: Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical study. Mod Pathol; 2009 Jul;22(7):977-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Lethal giant larvae (lgl) gene controls apical-basal polarity of epithelial cells in Drosophila, and has properties of a tumor-suppressor gene.
  • Routinely processed pathology specimens including 94 benign mucosae of digestive organs, in addition to 36 reactive gastropathy, 57 gastric epithelial dysplasia, and 77 gastric adenocarcinomas, were immunostained for Lgl2 protein.
  • Normal esophageal, duodenal, colonic, biliary, and pancreatic duct mucosae, as well as gastric intestinal metaplasia, did not express Lgl2.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cytoskeletal Proteins / metabolism. Gastric Mucosa / metabolism. Precancerous Conditions / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407852.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Hugl-2 protein, human
  •  go-up   go-down


83. Hajdú N, Zsoldos P, Neuberger G: [Rectum tumor diagnosed by subcutaneous emphysema of the chest]. Magy Seb; 2009 Oct;62(5):308-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rectum tumor diagnosed by subcutaneous emphysema of the chest].
  • BACKGROUND: Various benign and malignant thoracic or abdominal diseases can cause subcutaneous emphysema on the chest, pneumomediastinum or pneumopericardium.
  • To date only 7 cases have been reported on perforation of the sigmoid colon or the rectum presenting with these rare symptoms.
  • Further examination revealed that this was caused by a rectal tumor causing large bowel obstruction and a consequent perforation of the transverse colon.
  • [MeSH-major] Colonic Diseases / surgery. Intestinal Obstruction / surgery. Rectal Neoplasms / complications. Rectal Neoplasms / diagnosis. Subcutaneous Emphysema / etiology


84. Olesen SH, Christensen LL, Sørensen FB, Cabezón T, Laurberg S, Orntoft TF, Birkenkamp-Demtröder K: Human FK506 binding protein 65 is associated with colorectal cancer. Mol Cell Proteomics; 2005 Apr;4(4):534-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a previously published microarray study an EST (W80763), later identified as the gene hFKBP10 (NM_021939), was found to be strongly expressed in tumors while absent in the normal mucosa.
  • Analysis of 31 colorectal adenocarcinomas and 14 normal colorectal mucosa by RealTime PCR for hFKBP10 showed a significant up-regulation in tumors, when compared with normal mucosa.
  • Immunohistochemical analysis of 26 adenocarcinomas and matching normal mucosa, as well as benign hyperplastic polyps and adenomas, using a monoclonal anti-hFKBP65 antibody, showed that the protein was not present in normal colorectal epithelial cells, but strongly expressed in the tumor cells of colorectal cancer.
  • The protein was also expressed in fibroblasts of both normal mucosa and tumor tissue.
  • Western blot analysis of matched tumors and normal mucosa supported the finding of increased hFKBP65 expression in tumors compared with normal mucosa, in addition to identifying the molecular mass of hFKBP65 to approximately 72 kDa.
  • [MeSH-minor] Adenoma / pathology. Aged. Aged, 80 and over. Amino Acid Sequence. Animals. Antibodies, Monoclonal / metabolism. Binding Sites. Blotting, Western. COS Cells. Cercopithecus aethiops. Colonic Polyps / pathology. Electrophoresis, Gel, Two-Dimensional. Electrophoresis, Polyacrylamide Gel. Female. Gene Expression Regulation, Neoplastic. Humans. Hyperplasia. Immunohistochemistry. Intestinal Mucosa / cytology. Isoelectric Point. Male. Microscopy, Fluorescence. Middle Aged. Molecular Sequence Data. Molecular Weight. Polymerase Chain Reaction. Protein Binding. Transfection

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671042.001).
  • [ISSN] 1535-9476
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; EC 5.2.1.- / Tacrolimus Binding Proteins
  •  go-up   go-down


85. Merchant NB, Parikh AA, Kooby DA: Should all distal pancreatectomies be performed laparoscopically? Adv Surg; 2009;43:283-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are both enough experience and data (though retrospective) to confirm that LDP with or without spleen preservation appears to be a safe treatment for benign or noninvasive lesions of the pancreas.
  • Based on the fact that LDP can be performed with similar or shorter operative times, blood loss, complication rates, and length of hospital stay than ODP, it can be recommended as the treatment of choice for benign and noninvasive lesions in experienced hands when clinically indicated.
  • It is very difficult to make clear recommendations with regard to laparoscopic resection of malignant pancreatic tumors due to the lack of conclusive data.
  • Can we enucleate a small tumor off the pancreatic body by passing an endoscope through the gastric (or colonic) wall, and bring the specimen out via the mouth or anus?

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19845186.001).
  • [ISSN] 0065-3411
  • [Journal-full-title] Advances in surgery
  • [ISO-abbreviation] Adv Surg
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 95
  •  go-up   go-down


86. Elkharwily A, Gottlieb K: The pancreas in familial adenomatous polyposis. JOP; 2008;9(1):9-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The adenomatous polyposis coli gene functions as a tumor suppressor with hundreds of known mutations that result in a defective adenomatous polyposis coli protein.
  • In addition to the certain fate of colon cancer without colectomy, patients with familial adenomatous polyposis are also at increased risk for other types of neoplasms, including those which affect the pancreas.
  • This review focuses on periampullary and ampullary tumors, benign and malignant pancreatic neoplasms that are associated with familial adenomatous polyposis and Gardner syndrome and pancreatitis in these patients.
  • [MeSH-minor] Ampulla of Vater / pathology. Colonic Neoplasms / epidemiology. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Humans. Pancreatitis / epidemiology. Pancreatitis / pathology. Risk Factors


87. Carvalho J, Fullen D, Lowe L, Su L, Ma L: The expression of CD23 in cutaneous non-lymphoid neoplasms. J Cutan Pathol; 2007 Sep;34(9):693-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its utility in cutaneous epithelial tumors has never been studied.
  • METHODS: Immunohistochemical staining of CD23 was performed in a total of 131 cases of apocrine, eccrine, follicular and other cutaneous non-lymphoid tumors.
  • RESULTS: CD23 expression was detected in all benign apocrine tumors and in half of benign eccrine tumors, particularly those derived from secretory coils.
  • CD23 staining was seen in 42% (8/19) of microcystic adnexal carcinoma (MAC), while no staining was observed in tumor cells of desmoplastic trichoepithelioma, morpheaform basal cell carcinoma and syringoma.
  • In addition, CD23 reacted diffusely with cutaneous mucinous eccrine carcinoma in a manner similar to breast or colonic adenocarcinoma.
  • CONCLUSION: CD23 appears to be a reliable immunohistochemical marker of the eccrine/apocrine secretory coil and helpful in identifying sweat gland tumors of such origin.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Neoplasms, Adnexal and Skin Appendage / metabolism. Receptors, IgE / metabolism. Sweat Gland Neoplasms / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696916.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, IgE
  •  go-up   go-down


88. Grieco MJ, Shantha Kumara HM, Baxter R, Dujovny N, Kalady MF, Cekic V, Luchtefeld M, Whelan RL: Minimally invasive colorectal resection is associated with a rapid and sustained decrease in plasma levels of epidermal growth factor (EGF) in the colon cancer setting. Surg Endosc; 2010 Oct;24(10):2617-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive colorectal resection is associated with a rapid and sustained decrease in plasma levels of epidermal growth factor (EGF) in the colon cancer setting.
  • BACKGROUND: Epidermal growth factor (EGF) stimulates tumor growth directly via tumor cell EGF receptors or indirectly via its proangiogenic effects.
  • This study's purpose was to determine the impact of minimally invasive colorectal resection (MICR) on postoperative (postop) plasma EGF levels in the colorectal cancer (CRC) and benign disease settings and to see if preoperative (PreOp) EGF levels are altered in cancer patients.
  • METHODS: MICR patients with benign pathology (n = 40) and CRC (n = 48) had blood samples taken PreOp and on postoperative days (POD) 1 and 3.
  • RESULTS: The cancer and benign groups were comparable except for age.
  • The mean PreOp CRC plasma EGF level (122.9 ± 75.9 pg/ml) was significantly higher than that of the benign group (85.3 ± 38.5 pg/ml) (p = 0.015).
  • The benign group's POD3 and POD7-14 EGF levels were significantly lower than the PreOp level; later levels returned toward baseline.
  • MICR is associated with a significant decrease in EGF levels early postop in both cancer and benign settings.
  • Unlike the benign group, EGF blood levels in cancer patients remain low during the second postop month.
  • EGF may have value as a tumor marker.
  • [MeSH-major] Colectomy. Colonic Neoplasms / surgery. Epidermal Growth Factor / blood. Laparoscopy
  • [MeSH-minor] Aged. Colonic Diseases / blood. Colonic Diseases / surgery. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2011 Aug;25(8):2766-7; author reply 2768 [21416177.001]
  • [Cites] Cancer Res. 1974 Aug;34(8):2109-13 [4842257.001]
  • [Cites] Surg Endosc. 2008 Feb;22(2):287-97 [18204877.001]
  • [Cites] Gynecol Oncol. 1996 Feb;60(2):283-7 [8631552.001]
  • [Cites] Cancer Res. 1988 Sep 15;48(18):5119-23 [3044581.001]
  • [Cites] Cancer Res. 1996 Aug 15;56(16):3823-30 [8706030.001]
  • [Cites] Gut. 1996 Apr;38(4):582-6 [8707092.001]
  • [Cites] Int J Cancer. 1990 Jun 15;45(6):1018-21 [2351482.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3716-25 [15867367.001]
  • [Cites] Ann Surg. 2009 Jun;249(6):973-7 [19474682.001]
  • [Cites] Surgery. 1986 Aug;100(2):273-7 [3738755.001]
  • [Cites] Surgery. 1987 Jul;102(1):71-8 [3495896.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1293-6 [9137488.001]
  • [Cites] Anticancer Res. 1997 Jan-Feb;17(1B):613-9 [9066588.001]
  • [Cites] Surg Endosc. 1999 Mar;13(3):233-5 [10064753.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):162-5 [8391303.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Mol Biol Cell. 1993 Jan;4(1):121-33 [7680247.001]
  • [Cites] Surg Endosc. 1998 Aug;12(8):1035-8 [9685537.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):353-62 [16474912.001]
  • [Cites] Surgery. 2003 Sep;134(3):432-6 [14555930.001]
  • [Cites] J Clin Invest. 1992 Oct;90(4):1352-60 [1401070.001]
  • [Cites] Br J Surg. 1985 Oct;72(10):771-6 [2412626.001]
  • [Cites] Head Neck. 1992 Jan-Feb;14(1):8-13 [1624295.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):186-94 [10638988.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1523-30 [9403702.001]
  • (PMID = 20354877.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


89. Zhang X, Leav I, Revelo MP, Deka R, Medvedovic M, Jiang Z, Ho SM: Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon. PLoS Genet; 2009 Jan;5(1):e1000334
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon.
  • Alpha-methylacyl-coenzyme A racemase (AMACR) regulates peroxisomal beta-oxidation of phytol-derived, branched-chain fatty acids from red meat and dairy products -- suspected risk factors for colon carcinoma (CCa).
  • AMACR was first found overexpressed in prostate cancer but not in benign glands and is now an established diagnostic marker for prostate cancer.
  • By using a panel of immunostained-laser-capture-microdissected clinical samples comprising the entire colon adenoma-carcinoma sequence, we show that deregulation of AMACR during colon carcinogenesis involves two nonrandom events, resulting in the mutually exclusive existence of double-deletion at CG3 and CG10 and deletion of CG12-16 in a newly identified CpG island within the core promoter of AMACR.
  • It existed in histologically normal colonic glands and tubular adenomas with low AMACR expression and was absent in villous adenomas and all CCas expressing variable levels of AMACR.
  • Our findings identified key in vivo events and novel transcription factors responsible for AMACR regulation in CCas and suggested these AMACR deletions may have diagnostic/prognostic value for colon carcinogenesis.
  • [MeSH-major] Colon / enzymology. Colonic Neoplasms / genetics. CpG Islands / genetics. Gene Expression Regulation, Neoplastic. Promoter Regions, Genetic. Racemases and Epimerases / genetics
  • [MeSH-minor] Adenoma, Villous / genetics. Adenoma, Villous / metabolism. Adenoma, Villous / pathology. Base Sequence. Binding Sites. Cell Differentiation. Cell Line, Tumor. Humans. Molecular Sequence Data. Polymorphism, Genetic. Repressor Proteins / metabolism. Sequence Deletion / genetics. Transcription, Genetic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):15685-90 [10748193.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):79-92 [11438457.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] J Lipid Res. 2002 Mar;43(3):438-44 [11893780.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1662-70 [11926890.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2220-6 [11956072.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):926-31 [12131161.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):841-8 [12213712.001]
  • [Cites] Science. 2002 Sep 13;297(5588):1807-8; discussion 1807-8 [12229925.001]
  • [Cites] Hum Pathol. 2003 Mar;34(3):228-33 [12673556.001]
  • [Cites] J Lipid Res. 2003 May;44(5):968-77 [12611910.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):775-83 [12917210.001]
  • [Cites] Hum Pathol. 2003 Aug;34(8):792-6 [14506641.001]
  • [Cites] Cancer Detect Prev. 2003;27(6):422-6 [14642549.001]
  • [Cites] J Cell Biochem. 2004 Jan 1;91(1):47-53 [14689581.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):787-93 [14982833.001]
  • [Cites] Histopathology. 2004 Sep;45(3):218-25 [15330799.001]
  • [Cites] Cell. 1980 Oct;21(3):653-68 [6985477.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Int J Cancer. 1992 May 28;51(3):386-9 [1592529.001]
  • [Cites] Genome Res. 2007 Jun;17(6):807-17 [17567999.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1536-42 [17684125.001]
  • [Cites] Prostate. 2007 Oct 1;67(14):1487-97 [17680641.001]
  • [Cites] Prostate. 2007 Oct 1;67(14):1507-13 [17683075.001]
  • [Cites] Oncogene. 2007 Nov 15;26(52):7346-54 [17525739.001]
  • [Cites] Environ Health Perspect. 2008 Jun;116(6):769-76 [18560533.001]
  • [Cites] Genome Res. 2008 Nov;18(11):1763-77 [18836037.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;301:259-81 [16570852.001]
  • [Cites] Am J Hum Genet. 1992 Dec;51(6):1325-33 [1463014.001]
  • [Cites] Hum Mol Genet. 1997 Jun;6(6):881-5 [9175734.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1283-7 [10098773.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2970-4 [15710887.001]
  • [Cites] Mol Cancer Res. 2005 Feb;3(2):110-8 [15755877.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):316-23 [15599942.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):341-6 [15602744.001]
  • [Cites] Bioinformatics. 2005 Jul 1;21(13):2933-42 [15860560.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):252-5 [16082251.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Sep;20(9):1410-5 [16105129.001]
  • [Cites] Clin Transl Oncol. 2006 Jun;8(6):391-8 [16790391.001]
  • [Cites] Atherosclerosis. 2006 Sep;188(1):43-50 [16289551.001]
  • [Cites] Cancer Causes Control. 2007 Feb;18(1):41-50 [17315319.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):850-6 [17442371.001]
  • [Cites] J Med Chem. 2007 May 31;50(11):2700-7 [17477519.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):175-80 [17525630.001]
  • (PMID = 19148275.001).
  • [ISSN] 1553-7404
  • [Journal-full-title] PLoS genetics
  • [ISO-abbreviation] PLoS Genet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA112532; United States / NCI NIH HHS / CA / R01 CA112532; United States / NIEHS NIH HHS / ES / P30 ES006096; United States / NCI NIH HHS / CA / R01 CA015776; United States / NCI NIH HHS / CA / CA015776; United States / NCI NIH HHS / CA / R01 CA062269; United States / NCI NIH HHS / CA / CA062269
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Repressor Proteins; 0 / ZNF202 protein, human; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  • [Other-IDs] NLM/ PMC2613032
  •  go-up   go-down


90. Ma TL, Ni PH, Zhong J, Tan JH, Qiao MM, Jiang SH: Low expression of XIAP-associated factor 1 in human colorectal cancers. Chin J Dig Dis; 2005;6(1):10-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aims of the present study were: (i) to investigate the expression of XAF1 in human colorectal cancers (CRC) both in vitro and in vivo, and (ii) to evaluate the possibility of XAF1 as a new tumor marker.
  • METHODS: The expression of XAF1 in four human colon cancer cell lines (Colo205, Colo320, SW1116, LoVo) and in samples from 70 patients with CRC was analyzed by reverse transcriptase-polymerase chain reaction.
  • RESULTS: A low concentration of XAF1 mRNA was detectable in the three colon cancer cell lines other than Colo205, which showed the strongest expression of XAF1.
  • The expression of XAF1 in tissue was relatively lower in primary CRC compared with a relatively higher level in benign colorectal tumors (P < 0.01).
  • Although the XAF1 expression in circulation of those with CRC was also lower than in those with benign tumors, there was no statistical significance (P > 0.05).
  • CONCLUSIONS: The present results suggest that the low expression of XAF1 in tumor tissue coincides with a similar level in the peripheral circulation, which contributes at least part to the malignant behavior of CRC.
  • Integrating the XAF1 relative expression value with the other three traditional tumor biomarkers created a four-parameter assay that significantly improved the rate of diagnosis of CRC.
  • [MeSH-major] Biomarkers, Tumor / blood. Colonic Neoplasms / genetics. Colonic Neoplasms / physiopathology. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Aged. Apoptosis. Case-Control Studies. Female. Gene Expression Profiling. Humans. Intracellular Signaling Peptides and Proteins. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Zinc Fingers

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667552.001).
  • [ISSN] 1443-9611
  • [Journal-full-title] Chinese journal of digestive diseases
  • [ISO-abbreviation] Chin J Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / XAF1 protein, human
  •  go-up   go-down


91. Tedesco MM, Curet MJ: Laparoscopic-assisted colectomy for colon cancer. Expert Rev Med Devices; 2006 Jul;3(4):415-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic-assisted colectomy for colon cancer.
  • Laparoscopic-assisted colectomy (LAC) for colon cancer was first described in 1991.
  • Unlike other laparoscopic procedures used to treat benign disease, the LAC for colon cancer has been slow to gain acceptance for a variety of reasons.
  • Recently, several large, randomized controlled trials have demonstrated that LACs are comparable with open colectomies with respect to oncological issues such as survival, port-site metastases and tumor recurrence.
  • Moreover, there are significant patient benefits with the use of LAC including duration of analgesic use, return of bowel function, length of stay and return to normal activity.
  • [MeSH-major] Colectomy. Colonic Neoplasms / surgery. Laparoscopy
  • [MeSH-minor] Humans. Length of Stay. Neoplasm Recurrence, Local. Quality of Life. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16866638.001).
  • [ISSN] 1743-4440
  • [Journal-full-title] Expert review of medical devices
  • [ISO-abbreviation] Expert Rev Med Devices
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


92. Sheehan CE, Bartlett MB, Ganesan N, Preet A, Ross JS, FitzGerald KT: Epigenetic regulator MLL2 shows altered expression in cancer cell lines and tumors from human breast and colon. Cancer Cell Int; 2010 Apr 30;10:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic regulator MLL2 shows altered expression in cancer cell lines and tumors from human breast and colon.
  • In light of this difference, and previous reports on involvement of epigenetic regulators in malignancies, we investigated MLL2 expression in established cell lines from breast and colon tissues.
  • We then investigated MLL2 in solid tumors of breast and colon by immunohistochemistry, and evaluated potential associations with established clinicopathologic variables.
  • RESULTS: We examined MLL2 at both transcript and protein levels in established cell lines from breast and colon cancers.
  • Furthermore, we also identified incomplete proteolytic cleavage of MLL2 in the highly invasive tumor cell lines.
  • To corroborate these results, we studied tumor tissues from patients by immunohistochemistry.
  • Patient samples also revealed increased levels of MLL2 protein in invasive carcinomas of the breast and colon.
  • In breast, cytoplasmic MLL2 was significantly increased in tumor tissues compared to adjacent benign epithelium (p < 0.05), and in colon, both nuclear and cytoplasmic immunostaining was significantly increased in tumor tissues compared to adjacent benign mucosa (p < 0.05).
  • CONCLUSION: Our study indicates that elevated levels of MLL2 in the breast and colon cells are associated with malignancy in these tissues, in contrast to MLL involvement in haematopoietic cancer.
  • In addition, both abnormal cellular localization of MLL2 and incomplete proteolytic processing may be associated with tumor growth/progression in breast and colonic tissues.

  • Genetics Home Reference. consumer health - KMT2D gene.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1978 May;38(5):1345-55 [565251.001]
  • [Cites] Proc R Soc Med. 1937 Feb;30(4):371-6 [19990989.001]
  • [Cites] J Clin Invest. 1992 Sep;90(3):815-21 [1381724.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Cancer Res. 1989 Jun 15;49(12):3401-6 [2720694.001]
  • [Cites] Genomics. 1999 Jul 15;59(2):187-92 [10409430.001]
  • [Cites] Oncogene. 1999 Dec 23;18(56):7975-84 [10637508.001]
  • [Cites] Trends Biochem Sci. 2002 Aug;27(8):396-402 [12151224.001]
  • [Cites] Breast Cancer Res. 2003;5(2):89-95 [12631387.001]
  • [Cites] Trends Genet. 2003 Nov;19(11):629-39 [14585615.001]
  • [Cites] Science. 2003 Dec 12;302(5652):1972-5 [14671306.001]
  • [Cites] Mol Cell. 2004 Feb 27;13(4):587-97 [14992727.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5702-11 [15313910.001]
  • [Cites] Oncol Rep. 2004 Oct;12(4):701-7 [15375488.001]
  • [Cites] Int J Biochem Cell Biol. 2005 May;37(5):1054-65 [15743678.001]
  • [Cites] Development. 2006 Apr;133(8):1423-32 [16540515.001]
  • [Cites] Acta Oncol. 2006;45(4):375-88 [16760173.001]
  • [Cites] DNA Repair (Amst). 2006 Sep 8;5(9-10):1265-72 [16797254.001]
  • [Cites] Genes Dev. 2006 Sep 1;20(17):2397-409 [16951254.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15392-7 [17021013.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] Nutrition. 2007 Jan;23(1):81-6 [17189090.001]
  • [Cites] Mol Biol Cell. 2007 Jun;18(6):2356-66 [17429066.001]
  • [Cites] Mol Cell. 2007 Aug 17;27(4):573-84 [17707229.001]
  • [Cites] Nat Cell Biol. 2008 Jan;10(1):77-84 [18066051.001]
  • [Cites] Mol Endocrinol. 2008 Jun;22(6):1312-9 [18372346.001]
  • [Cites] J Biol Chem. 2008 Dec 12;283(50):35258-64 [18840606.001]
  • [Cites] Epigenetics Chromatin. 2009;2(1):5 [19348672.001]
  • [Cites] J Natl Cancer Inst. 1977 Feb;58(2):209-14 [833871.001]
  • (PMID = 20433758.001).
  • [ISSN] 1475-2867
  • [Journal-full-title] Cancer cell international
  • [ISO-abbreviation] Cancer Cell Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2878298
  •  go-up   go-down


93. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J: SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem; 2009 Jul 3;284(27):18210-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.
  • Determination of SirT1 function in tumor cells is important for its targeting in cancer therapy.
  • We found that SirT1 knockdown by short hairpin RNA accelerates tumor xenograft formation by HCT116 cells, whereas SirT1 overexpression inhibits tumor formation.
  • Immunohistochemical staining revealed high level SirT1 in normal colon mucosa and benign adenomas.
  • SirT1 overexpression was observed in approximately 25% of stage I/II/III colorectal adenocarcinomas but rarely found in advanced stage IV tumors.
  • These results suggest a rationale for the use of SirT1 activators and inhibitors in the prevention and treatment of colon cancer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 17;403(6771):795-800 [10693811.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2126-8 [11000115.001]
  • [Cites] Nature. 2001 Mar 8;410(6825):227-30 [11242085.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] Nature. 2003 Sep 11;425(6954):191-6 [12939617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10794-9 [12960381.001]
  • [Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]
  • [Cites] EMBO J. 2004 Jun 16;23(12):2369-80 [15152190.001]
  • [Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Nature. 2005 Mar 3;434(7029):113-8 [15744310.001]
  • [Cites] Cell Metab. 2005 Jul;2(1):67-76 [16054100.001]
  • [Cites] Cell Metab. 2005 Aug;2(2):105-17 [16098828.001]
  • [Cites] Cell. 2005 Nov 4;123(3):437-48 [16269335.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10457-63 [16288037.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):28-38 [16354677.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):176-85 [16170353.001]
  • [Cites] PLoS Biol. 2006 Feb;4(2):e31 [16366736.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4368-77 [16618762.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):1025-31 [16892051.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8122-35 [16923962.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):337-42 [17086191.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1109-22 [17112576.001]
  • [Cites] Mol Cell. 2007 Feb 23;25(4):543-57 [17317627.001]
  • [Cites] Arch Dermatol Res. 2007 May;299(2):103-6 [17180656.001]
  • [Cites] Mol Cell. 2007 Jul 6;27(1):149-62 [17612497.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6612-8 [17638871.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5489-504 [17694089.001]
  • [Cites] Biochem J. 2007 Nov 1;407(3):451-60 [17620057.001]
  • [Cites] Biotechnol J. 2007 Nov;2(11):1360-8 [17806102.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):712-6 [18046409.001]
  • [Cites] Mol Biol Cell. 2008 Mar;19(3):1210-9 [18184747.001]
  • [Cites] PLoS One. 2008;3(4):e2020 [18414679.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):312-23 [18835033.001]
  • (PMID = 19433578.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / R01 CA112215-03; United States / NCI NIH HHS / CA / CA121291; United States / NCI NIH HHS / CA / R01 CA121291; United States / NCI NIH HHS / CA / CA112215-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Small Interfering; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2709385
  •  go-up   go-down


94. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE, Kinzler KW, Vogelstein B, Willis J, Markowitz SD: Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A; 2008 Mar 18;105(11):4283-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative lesion sequencing provides insights into tumor evolution.
  • We show that the times separating the birth of benign, invasive, and metastatic tumor cells can be determined by analysis of the mutations they have in common.
  • When combined with prior clinical observations, these analyses suggest the following general conclusions about colorectal tumorigenesis: (i) It takes approximately 17 years for a large benign tumor to evolve into an advanced cancer but <2 years for cells within that cancer to acquire the ability to metastasize;.
  • (iii) the process of cell culture ex vivo does not introduce new clonal mutations into colorectal tumor cell populations; and (iv) the rates at which point mutations develop in advanced cancers are similar to those of normal cells.
  • These results have important implications for understanding human tumor pathogenesis, particularly those associated with metastasis.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):776-81 [12552134.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11476-9; discussion 11479-80 [18089773.001]
  • [Cites] World J Surg. 2004 Mar;28(3):263-70 [14961200.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] Humangenetik. 1972;16(1):87-110 [4647448.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] Br J Cancer. 1982 Nov;46(5):773-81 [7171456.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1650-5 [6299526.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6109-14 [3167857.001]
  • [Cites] Science. 1989 Apr 14;244(4901):217-21 [2649981.001]
  • [Cites] Cytometry. 1989 Nov;10(6):673-80 [2684578.001]
  • [Cites] Br J Cancer. 1990 Mar;61(3):382-4 [2328202.001]
  • [Cites] Int J Cancer. 1990 May 15;45(5):968-71 [2159442.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7717-22 [2253215.001]
  • [Cites] Br J Surg. 1991 Jan;78(1):60-6 [1998868.001]
  • [Cites] Science. 1995 Jun 2;268(5215):1336-8 [7761852.001]
  • [Cites] Br J Cancer. 1995 Aug;72(2):435-41 [7640229.001]
  • [Cites] Nat Genet. 1996 Jul;13(3):343-6 [8673134.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Cytometry. 1997 Nov 1;29(3):273-8 [9389445.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):213-22 [9748584.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):803-11 [10091757.001]
  • [Cites] Eur J Surg Oncol. 1999 Jun;25(3):292-6 [10336810.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1963 Oct;90:673-87 [14068399.001]
  • [Cites] Cell Cycle. 2004 Oct;3(10):1221-4 [15467468.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8111-7 [16166284.001]
  • [Cites] Cell Cycle. 2006 Mar;5(6):610-4 [16582617.001]
  • [Cites] Cancer Sci. 2006 May;97(5):362-7 [16630132.001]
  • [Cites] Nat Methods. 2006 Jul;3(7):551-9 [16791214.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Arch Surg. 2006 Dec;141(12):1220-6; discussion 1227 [17178965.001]
  • [Cites] Curr Biol. 2007 Apr 3;17(7):R233-6 [17407749.001]
  • [Cites] Nat Protoc. 2006;1(2):859-69 [17406318.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11471-5 [18089772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8817-22 [12857956.001]
  • (PMID = 18337506.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA57345; United States / NCI NIH HHS / CA / R37 CA043460; United States / NCI NIH HHS / CA / R01 CA127306; United States / NCI NIH HHS / CA / CA121113; United States / NIGMS NIH HHS / GM / GM078986; United States / NCI NIH HHS / CA / CA127306; United States / NCI NIH HHS / CA / P50 CA062924; United States / NIGMS NIH HHS / GM / R01 GM078986; United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / R01 CA120237; United States / NCI NIH HHS / CA / R01 CA121113; United States / NIGMS NIH HHS / GM / GM078986-02; United States / NCI NIH HHS / CA / P30 CA043703; United States / NCI NIH HHS / CA / CA43460; United States / NCI NIH HHS / CA / CA043703; United States / NCI NIH HHS / CA / CA120237; United States / NCI NIH HHS / CA / U54 CA116867; United States / NIGMS NIH HHS / GM / R01 GM078986-02; United States / NCI NIH HHS / CA / CA116867; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / R37 CA057345; United States / NCI NIH HHS / CA / R01 CA057345; United States / NCI NIH HHS / CA / R01 CA105090
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC2393770
  •  go-up   go-down


95. Zmora O, Benjamin B, Reshef A, Neufeld D, Rosin D, Klein E, Ayalon A, Shpitz B: Laparoscopic colectomy for colonic polyps. Surg Endosc; 2009 Mar;23(3):629-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colectomy for colonic polyps.
  • BACKGROUND: Benign colonic polyps not amenable to colonoscopic resection or those containing carcinoma require surgical excision.
  • The aim of this study was to review our experience with the laparoscopic approach for retrieval of colonic polyps with specific emphasis on safety, feasibility, and tumor localization.
  • METHODS: Retrospective chart review of all patients who underwent laparoscopic colectomy for colonic polyps was performed.
  • RESULTS: Forty-nine patients (22 males, 27 males, mean age 66 years) underwent laparoscopic colectomy for colonic polyps.
  • Indications for surgery were presumably benign polyps in 38 patients, and superficial carcinoma in a polyp, diagnosed by colonoscopy, in 11; twenty-three patients underwent preoperative localization procedures.
  • In 7 of the 38 patients with presumably benign lesion, colon cancer was diagnosed in the colectomy specimen.
  • CONCLUSIONS: Laparoscopic surgery for the treatment of colonic polyps seems to be feasible and safe, with a low complication rate.
  • Tumor localization is crucial for adequate resection.
  • Although one-fifth of presumably benign polyps harbored cancer, none of these patients had positive lymph nodes.
  • [MeSH-major] Colectomy / methods. Colonic Polyps / surgery. Laparoscopy / methods

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2006 Apr;30(4):605-11 [16555023.001]
  • [Cites] Surg Endosc. 2002 May;16(5):808-11 [11997827.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1111-24 [15449261.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):177-81 [12892794.001]
  • [Cites] World J Surg. 2007 Jul;31(7):1491-5 [17534547.001]
  • [Cites] Dis Colon Rectum. 1999 Oct;42(10):1353-5 [10528779.001]
  • [Cites] Ann Surg. 2006 Jun;243(6):730-5; discussion 735-7 [16772776.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003145 [16034888.001]
  • [Cites] Dis Colon Rectum. 2006 Jun;49(6):879-82 [16598402.001]
  • [Cites] J Gastrointest Surg. 2007 Sep;11(9):1197-9 [18062067.001]
  • [Cites] Dis Colon Rectum. 1999 Jun;42(6):819-22 [10378609.001]
  • [Cites] Am J Surg. 2006 Nov;192(5):644-8 [17071200.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):400-3 [17180271.001]
  • (PMID = 19067054.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


96. Lebeau R, Koffi E, Diané B, Amani A, Kouassi JC: [Acute intestinal intussusceptions in adults: analysis of 20 cases]. Ann Chir; 2006 Oct;131(8):447-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Invaginations intestinales aiguës de l'adulte: analyse d'une série de 20 cas.
  • The clinical and radiological findings were suggestive of bowel obstruction (N = 14), peritonitis (N = 5) and appendicular abscess (N = 1).
  • Necrosis was found in the intussusceptum in 10 cases and a tumor on the lead point in 14 cases (5 benign lesions and 9 malignant ones).
  • For intussusception involving the colon, all patients underwent en bloc resection with immediate anastomosis, while intussusception located on the small bowel were treated by surgical reduction (N = 1), en bloc resection (N = 8) with immediate (N = 7) or delayed (N = 1) anastomosis.
  • En bloc resection is recommended because of the frequency of neoplasms and bowel ischemia.
  • [MeSH-major] Colonic Diseases / surgery. Ileal Diseases / surgery. Ileocecal Valve. Intussusception / surgery. Jejunal Diseases / surgery

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16765901.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


97. Pulitzer M, Xu R, Suriawinata AA, Waye JD, Harpaz N: Microcarcinoids in large intestinal adenomas. Am J Surg Pathol; 2006 Dec;30(12):1531-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Composite adenoma-carcinoid tumors are rare colorectal lesions consisting of intermingled adenomatous and carcinoid components.
  • Unlike other mixed endocrine-glandular colorectal neoplasms, which are generally malignant, their glandular component is histologically benign and their natural history is favorable.
  • We present 4 cases of colonic adenomas containing microcarcinoids, a hitherto undescribed lesion that is either a precursor of composite adenoma-carcinoids or a related but independent entity.
  • The cases, identified among our surgical and consultation files, were endoscopically routine sessile polyps removed from 4 otherwise normal individuals, 3 from the cecum and 1 from the distal colon.
  • The patients' clinical course was benign on the basis of 2 years' median follow-up (range, 6 mo to 10 y).
  • Two patients with incomplete polypectomies underwent hemicolectomy revealing no residual endocrine neoplasia.
  • Awareness of microcarcinoids in colonic adenomas should help avert potential diagnostic pitfalls posed by their pleomorphism, basal location, and infiltrative patterns, and may help clarify their natural history and possible relationship to composite glandular-carcinoid tumors.
  • [MeSH-major] Adenoma / pathology. Carcinoid Tumor / pathology. Intestinal Neoplasms / pathology. Intestine, Large / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Female. Humans. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122508.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


98. Van Patten K, Parkash V, Jain D: Cadherin expression in gastrointestinal tract endometriosis: possible role in deep tissue invasion and development of malignancy. Mod Pathol; 2010 Jan;23(1):38-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 38 cases (peritoneal endometriosis (n=14), gastrointestinal endometriosis (n=21: 11 colon, 8 appendix, 2 small bowel), and 3 cases of endometrioid carcinoma arising in colonic endometriosis (n=3)) were included in the study.
  • All three cases of carcinoma arising in colonic endometriosis showed a total loss of N-cadherin in the tumor, but preserved E-cadherin and beta-catenin expression.
  • In these cases, areas of benign endometriotic glands near the tumor showed weak and focal N-cadherin expression that was gradually lost.


99. Mercier I, Vuolo M, Jasmin JF, Medina CM, Williams M, Mariadason JM, Qian H, Xue X, Pestell RG, Lisanti MP, Kitsis RN: ARC (apoptosis repressor with caspase recruitment domain) is a novel marker of human colon cancer. Cell Cycle; 2008 Jun 1;7(11):1640-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ARC (apoptosis repressor with caspase recruitment domain) is a novel marker of human colon cancer.
  • Recently, however, the abundance of ARC was noted to be markedly increased in the epithelium of primary human breast cancers compared with benign breast tissue and to confer chemo- and radiation-resistance.
  • Whether the induction of ARC is specific to breast cancer or a more general feature of neoplasia remains unknown.
  • In this study, we assessed the abundance and subcellular localization of ARC in 21 human colon cancer cell lines and in 44 primary human colon adenocarcinomas and adjacent benign colonic tissue.
  • ARC was present at high levels in most colon cancer cell lines and in almost all primary colon cancers compared with corresponding controls.
  • Levels of ARC in the cytoplasm were increased in well, moderately, and poorly differentiated cancers compared with benign tissue, while levels of nuclear ARC were increased only in moderately differentiated tumors.
  • These results demonstrate that ARC is a novel marker of human colon cancer and suggest that it may be a general feature of epithelial cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptosis Regulatory Proteins / genetics. Biomarkers, Tumor / genetics. Colonic Neoplasms / metabolism. Muscle Proteins / genetics
  • [MeSH-minor] Cell Line, Tumor. Cytoplasm / metabolism. Humans. Immunoblotting. Immunohistochemistry

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469522.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA-098779; United States / NCI NIH HHS / CA / R01-CA-120876; United States / NCI NIH HHS / CA / R01-CA-80250; United States / NHLBI NIH HHS / HL / R01HL60665; United States / NHLBI NIH HHS / HL / R01HL61550; United States / NHLBI NIH HHS / HL / R01HL80607
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / Muscle Proteins; 0 / NOL3 protein, human
  •  go-up   go-down


100. Bonin EA, Baron TH: Update on the indications and use of colonic stents. Curr Gastroenterol Rep; 2010 Oct;12(5):374-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the indications and use of colonic stents.
  • Self-expandable metal stent (SEMS) placement is a minimally invasive option for achieving acute colonic decompression in obstructed colorectal cancer.
  • Colorectal stenting offers nonoperative, immediate, and effective colon decompression and allows bowel preparation for an elective oncologic resection.
  • Colonic stent placement also offers effective palliation of malignant colonic obstruction, although it carries risks of delayed complications.
  • Despite concerns of tumor seeding following endoscopic colorectal stent placement, no difference exists in oncologic long-term survival between patients who undergo stent placement followed by elective resection and those undergoing emergency bowel resection.
  • Colorectal stents have also been used in selected patients with benign colonic strictures.
  • Patients with benign colonic stricture with acute colonic obstruction who are at high risk for emergency surgery can gain temporary relief of obstruction after SEMS placement; the stent can be removed en bloc with the colon specimen at surgery.
  • This article reviews the techniques and indications of SEMS placement for benign and malignant colorectal obstructions.
  • [MeSH-minor] Acute Disease. Colon / pathology. Colon / surgery. Colonic Diseases / etiology. Colonic Diseases / surgery. Constriction, Pathologic / surgery. Humans. Palliative Care. Pelvic Neoplasms / complications. Pelvic Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2009 Oct;19(5):e202-5 [19851253.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1096-102 [12190673.001]
  • [Cites] Colorectal Dis. 2009 Feb;11(2):178-83 [18477021.001]
  • [Cites] Lancet. 2006 Nov 4;368(9547):1573-4 [17084754.001]
  • [Cites] Scand J Surg. 2009;98(3):143-7 [19919918.001]
  • [Cites] J Gastrointest Surg. 2009 May;13(5):960-5 [19159986.001]
  • [Cites] South Med J. 2009 Dec;102(12):1257-9 [20016435.001]
  • [Cites] World J Surg. 2009 Jun;33(6):1281-6 [19363580.001]
  • [Cites] Gastrointest Endosc. 2008 Jan;67(1):68-73 [18028916.001]
  • [Cites] J Am Coll Surg. 2001 Jun;192(6):719-25 [11400965.001]
  • [Cites] Brachytherapy. 2009 Jul-Sep;8(3):313-7 [19211311.001]
  • [Cites] Can J Gastroenterol. 2006 Dec;20(12):779-85 [17171197.001]
  • [Cites] Arch Surg. 2009 Dec;144(12):1127-32 [20026830.001]
  • [Cites] Surg Endosc. 2007 Feb;21(2):225-33 [17160651.001]
  • [Cites] Gastrointest Endosc. 2010 Apr;71(4):799-805 [20363422.001]
  • [Cites] Gastrointest Endosc. 2010 Mar;71(3):560-72 [20189515.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] AJR Am J Roentgenol. 2009 Jul;193(1):248-54 [19542421.001]
  • [Cites] Dis Colon Rectum. 2003 Jan;46(1):24-30 [12544518.001]
  • [Cites] World J Gastroenterol. 2007 Aug 7;13(29):3977-80 [17663513.001]
  • [Cites] Curr Oncol Rep. 2009 Jul;11(4):293-7 [19508834.001]
  • [Cites] Curr Opin Gastroenterol. 2009 Jan;25(1):50-4 [19119510.001]
  • [Cites] Scand J Gastroenterol. 2010 Jun;45(6):725-31 [20205505.001]
  • [Cites] Colorectal Dis. 2009 May;11(4):405-9 [18513190.001]
  • [Cites] Radiology. 2010 Mar;254(3):774-82 [20177092.001]
  • [Cites] Dis Colon Rectum. 2009 Sep;52(9):1657-61 [19690497.001]
  • [Cites] Dis Colon Rectum. 2009 Jul;52(7):1272-7 [19571704.001]
  • [Cites] J Am Coll Surg. 2010 Jan;210(1):45-53 [20123331.001]
  • [Cites] BMC Surg. 2007 Jul 03;7:12 [17608947.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3379-84 [19487380.001]
  • [Cites] Am Surg. 2009 Oct;75(10):897-900 [19886130.001]
  • [Cites] Expert Rev Gastroenterol Hepatol. 2008 Jun;2(3):399-409 [19072388.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2009 May;21(5):585-6 [19282771.001]
  • [Cites] Dig Dis Sci. 2010 Jun;55(6):1732-7 [19693667.001]
  • [Cites] Surg Endosc. 2010 Mar;24(3):525-30 [19597776.001]
  • [Cites] Colorectal Dis. 2011 May;13(5):549-54 [20082633.001]
  • [Cites] Dis Colon Rectum. 2010 Feb;53(2):200-12 [20087096.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2007 Apr;17(2):323-39, vi [17556151.001]
  • [Cites] Gastrointest Endosc. 2009 Jun;69(7):1282-7 [19286179.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):2051-7 [15447772.001]
  • [Cites] Gastrointest Endosc. 2009 Mar;69(3 Pt 2):675-80 [19251009.001]
  • [Cites] Surgery. 2008 Nov;144(5):786-92 [19081022.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Nov;7(11):1174-6 [19631290.001]
  • [Cites] Gastrointest Endosc. 2005 Jan;61(1):1-7 [15672048.001]
  • [Cites] Int J Colorectal Dis. 2008 Oct;23(10):1007-12 [18594837.001]
  • [Cites] Gastrointest Endosc. 2006 Dec;64(6):921-4 [17140899.001]
  • [Cites] Am J Gastroenterol. 2010 May;105(5):1087-93 [19935785.001]
  • [Cites] Surg Endosc. 2008 Feb;22(2):454-62 [17704890.001]
  • (PMID = 20703837.001).
  • [ISSN] 1534-312X
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down






Advertisement